A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

[1]  D. Shafritz,et al.  Analysis of Liver Disease, Nuclear HBcAg, Viral Replication, and Hepatitis B Virus DNA in Liver and Serum of HBcAg Vs. Anti‐HBe Positive Carriers of Hepatitis B Virus , 2007, Hepatology.

[2]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[3]  M. Sherman,et al.  80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) , 2006 .

[4]  J. Hoofnagle,et al.  Hepatitis B--preventable and now treatable. , 2006, The New England journal of medicine.

[5]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[6]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[7]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[8]  J. George,et al.  Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B , 2006 .

[9]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[10]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[11]  M. Kew,et al.  Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy , 2005, Journal of viral hepatitis.

[12]  F. Zoulim,et al.  Longitudinal Assessment of Histology Surrogate Markers (FibroTest–ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection , 2005, The American Journal of Gastroenterology.

[13]  C. Hannoun,et al.  Dynamic Range and Reproducibility of Hepatitis B Virus (HBV) DNA Detection and Quantification by Cobas Taqman HBV, a Real-Time Semiautomated Assay , 2005, Journal of Clinical Microbiology.

[14]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[15]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[16]  Y. Liaw,et al.  Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[17]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[18]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[19]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[20]  A. Lok,et al.  Sustained response after a 2‐year course of lamivudine treatment of hepatitis B e antigen‐negative chronic hepatitis B , 2004, Journal of viral hepatitis.

[21]  E. Keeffe,et al.  Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.

[22]  I. Suh,et al.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study , 2004, BMJ : British Medical Journal.

[23]  B. McMahon,et al.  Chronic hepatitis B: Update of recommendations , 2004, Hepatology.

[24]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[25]  D. Fong,et al.  Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. , 2003, Gastroenterology.

[26]  E. Cholongitas,et al.  Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen–negative chronic hepatitis B virus infection , 2003, American Journal of Gastroenterology.

[27]  H. Lee,et al.  Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. , 2003, Journal of hepatology.

[28]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[29]  E. Keeffe,et al.  Prophylaxis Against Chemotherapy-Induced Reactivation of Hepatitis B Virus Infection With Lamivudine , 2003, Journal of clinical gastroenterology.

[30]  H. Janssen,et al.  Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection , 2003, Journal of viral hepatitis.

[31]  F. Rousseau,et al.  Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.

[32]  E. Schiff,et al.  Durability of serologic response after lamivudine treatment of chronic hepatitis B , 2003, Hepatology.

[33]  J. Sung,et al.  A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis , 2003 .

[34]  Chee-Kin Hui,et al.  Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis‐related complications, and hepatocellular carcinoma , 2003, Hepatology.

[35]  Y. Jeng,et al.  Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients , 2003, Hepatology.

[36]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[37]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[38]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[39]  A. Lok,et al.  Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection , 2002, Hepatology.

[40]  Y. Liaw.  Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B , 2002, Journal of gastroenterology and hepatology.

[41]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[42]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[43]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[44]  S. Milani,et al.  Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. , 2002, Journal of hepatology.

[45]  H. Chiou,et al.  Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B , 2002, Hepatology.

[46]  A. Kidd,et al.  Genetic variability in hepatitis B viruses. , 2002, The Journal of general virology.

[47]  A. Lok,et al.  Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. , 2002, Gastroenterology.

[48]  A. Lok,et al.  Clinical significance of hepatitis B virus genotypes , 2002, Hepatology.

[49]  Ding‐Shinn Chen,et al.  Genotypes and Clinical Phenotypes of Hepatitis B Virus in Patients with Chronic Hepatitis B Virus Infection , 2002, Journal of Clinical Microbiology.

[50]  P. Marcellin,et al.  Baseline alt predicts histologic and serologic response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV) , 2002 .

[51]  R. Tubiana,et al.  Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV , 2002, Journal of Hepatology.

[52]  M. Brunetto,et al.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. , 2002, Journal of hepatology.

[53]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[54]  D. Vassilopoulos,et al.  Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.

[55]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study , 2001, The Lancet.

[56]  G. Barbarini,et al.  Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. , 2001, Journal of hepatology.

[57]  M. Buti,et al.  Two years of lamivudine therapy in anti‐HBe‐positive patients with chronic hepatitis B , 2001, Journal of Viral Hepatitis.

[58]  C. Bréchot,et al.  Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? , 2001, Hepatology.

[59]  M. Yuen,et al.  Long‐term follow‐up of interferon alfa treatment in chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis‐related complications , 2001, Hepatology.

[60]  H. Conjeevaram,et al.  Occult hepatitis B virus infection: A hidden menace? , 2001, Hepatology.

[61]  S. Hadziyannis,et al.  Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B , 2001 .

[62]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[63]  A. Lok,et al.  Management of hepatitis B: 2000--summary of a workshop. , 2001, Gastroenterology.

[64]  K. Koike,et al.  Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. , 2001, Gastroenterology.

[65]  R. Perrillo.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.

[66]  E. Schiff,et al.  A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B , 2001, Hepatology.

[67]  S. Hadziyannis,et al.  The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .

[68]  A. Heath,et al.  An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques , 2001, Vox sanguinis.

[69]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes and the response to interferon therapy. , 2000, Journal of hepatology.

[70]  H. Lee,et al.  Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea , 2000, Hepatology.

[71]  B. McMahon,et al.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study , 2000, Hepatology.

[72]  S. Hadziyannis,et al.  Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.

[73]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[74]  A. Gatta,et al.  Long term effect of alpha interferon in children with chronic hepatitis B , 2000, Gut.

[75]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[76]  T. Santantonio,et al.  Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. , 2000, Journal of hepatology.

[77]  J. Villeneuve,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.

[78]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[79]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[80]  Y. Liaw,et al.  Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B , 1999, Hepatology.

[81]  E. Jury.  EASL International Consensus Conference on Hepatitis C , 1999, Journal of hepatology.

[82]  E. Schiff,et al.  Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.

[83]  C. Chu,et al.  Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection , 1999, Hepatology.

[84]  M. Buti,et al.  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. , 1999, Hepatology.

[85]  C. Hunt,et al.  Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. , 1998 .

[86]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[87]  G. Fattovich,et al.  Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998, American Journal of Gastroenterology.

[88]  A. Magrini,et al.  Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels , 1997, Hepatology.

[89]  J. Hoofnagle,et al.  Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. , 1997, Gastroenterology.

[90]  J. Pawlotsky,et al.  Epidemiological factors affecting the severity of hepatitis C virus‐related liver disease: A French survey of 6,664 patients , 1997, Hepatology.

[91]  R. Wiesner,et al.  Liver Transplantation and Hepatitis B , 1997, Annals of Internal Medicine.

[92]  J. Hoofnagle,et al.  THE TREATMENT OF CHRONIC VIRAL HEPATITIS , 1997 .

[93]  R. Tubiana,et al.  Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men , 1996, Annals of Internal Medicine.

[94]  G. Marchesini,et al.  Efficacy of a surveillance program for early detection of hepatocellular carcinoma , 1996, Cancer.

[95]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[96]  F. Zoulim,et al.  Analysis of hepatitis B virus genotypes and pre‐core region variability during interferon treatment of HBe antigen negative chronic hepatitis B , 1996, Journal of medical virology.

[97]  H. Hsu,et al.  The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age , 1995, Hepatology.

[98]  E. Schiff,et al.  Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. , 1995, Gastroenterology.

[99]  M. Sherman,et al.  Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population , 1995, Hepatology.

[100]  E. Christensen,et al.  Occurrence of hepatocellular carcinoma and decompensation in western european patients with cirrhosis type B , 1995, Hepatology.

[101]  F Tsuda,et al.  Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen , 1994, Journal of virology.

[102]  A. Lok,et al.  Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. , 1993, Gastroenterology.

[103]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[104]  J. Hoofnagle,et al.  Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. , 1993, Gastroenterology.

[105]  R. D. de Man,et al.  Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. , 1992, Gastroenterology.

[106]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[107]  M. Colombo,et al.  Hepatocellular carcinoma in Italian patients with cirrhosis. , 1991, The New England journal of medicine.

[108]  H. Will,et al.  Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[109]  J. Hoofnagle,et al.  Long-term remission of chronic hepatitis B after alpha-interferon therapy. , 1991, Annals of internal medicine.

[110]  P. Tiollais,et al.  Hepatitis B virus. , 1991, Scientific American.

[111]  Kenzo Kobayashi,et al.  Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis , 1990, Hepatology.

[112]  H. Hsu,et al.  Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children , 1990, Hepatology.

[113]  M. Rugge,et al.  Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. , 1990, Gastroenterology.

[114]  H. Thomas,et al.  Which patients with chronic hepatitis B virus infection will respond to α‐interferon therapy? A statistical analysis of predictive factors , 1989, Hepatology.

[115]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[116]  A. Lok,et al.  A longitudinal follow‐up of asymptomatic hepatitis B surface antigen‐positive chinese children , 1988, Hepatology.

[117]  A. Lok,et al.  LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1988, The Lancet.

[118]  R. Beasley.  Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[119]  J. Hoofnagle,et al.  Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy. , 1987, Gastroenterology.

[120]  J. Hoofnagle,et al.  Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers , 1987 .

[121]  A. Lok,et al.  Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. , 1987, Gastroenterology.

[122]  R. Purcell,et al.  Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. , 1987, Gastroenterology.

[123]  M. Rugge,et al.  Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti‐HBe in chronic hepatitis type B , 1986, Hepatology.

[124]  H. Hsu,et al.  Early detection of hepatocellular carcinoma by real‐time ultrasonography. A prospective study , 1985, Cancer.

[125]  H. Hsu,et al.  Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. , 1985, Gastroenterology.

[126]  T R Bender,et al.  Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. , 1985, The Journal of infectious diseases.

[127]  J. Hoofnagle,et al.  Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. , 1981, Annals of internal medicine.

[128]  P. Johnson,et al.  Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. , 1980, Journal of the National Cancer Institute.

[129]  R. Michael.  B Virus Infection , 1966 .

[130]  G. Raimondo,et al.  Occult hepatitis B virus infection. , 2007, Journal of hepatology.

[131]  P. Marcellin,et al.  P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy , 2006 .

[132]  A. Cross,et al.  P.090 Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022) , 2006 .

[133]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[134]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[135]  P. Marcellin,et al.  424 Durability of HBEAG seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB) , 2004 .

[136]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[137]  E. Jury.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003 .

[138]  E. Schiff,et al.  The Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B , 2001 .

[139]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[140]  H. Margolis,et al.  Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. , 1999, American journal of public health.

[141]  B. Koblin,et al.  Hepatitis B virus infection. , 1998, The New England journal of medicine.

[142]  E. Christensen,et al.  Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study , 1994 .

[143]  M. Cottone,et al.  Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. , 1994, Journal of hepatology.

[144]  E. Schiff.  Treatment algorithms for hepatitis B and C. , 1993, Gut.

[145]  E. Kurstak.  Acute hepatitis B virus infection , 1993 .

[146]  J. Nielsen,et al.  High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. , 1991, Journal of acquired immune deficiency syndromes.

[147]  A. Lok,et al.  Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. , 1990, Journal of hepatology.

[148]  J. Hoofnagle,et al.  Viral hepatitis and liver disease , 1984 .